JWH-145
{{Short description|Chemical compound}}
{{Drugbox
| Verifiedfields =
| verifiedrevid =
| IUPAC_name = 1-naphthalenyl(1-pentyl-5-phenyl-1H-pyrrol-3-yl)-methanone
| image = JWH-145.svg
| width =
| tradename =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_CA = Schedule II
| legal_DE =
| legal_UK = Class B
| legal_US =
| legal_status =
| routes_of_administration =
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| CAS_number_Ref = {{cascite|correct}}
| CAS_number = 914458-19-8
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = JRT5F2Y0NA
| ATC_prefix =
| ATC_suffix =
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| PubChem = 44418304
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 23277878
| ChEMBL = 385940
| C=26 | H=25 | N=1 | O=1
| smiles = O=C(C1=CN(CCCCC)C(C2=CC=CC=C2)=C1)C3=C(C=CC=C4)C4=CC=C3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C26H25NO/c1-2-3-9-17-27-19-22(18-25(27)21-12-5-4-6-13-21)26(28)24-16-10-14-20-11-7-8-15-23(20)24/h4-8,10-16,18-19H,2-3,9,17H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = JLXYYSHMURZHKI-UHFFFAOYSA-N
}}
JWH-145 (1-naphthalenyl(1-pentyl-5-phenyl-1H-pyrrol-3-yl)-methanone) is a synthetic cannabinoid from the naphthoylpyrrole family which acts as an agonist of the CB1 (Ki = 14 ± 2nM) and CB2 (Ki = 6.4 ± 0.4nM) receptors, with a moderate (~2.2x) selectivity for the CB2 receptor. JWH-145 was first synthesized in 2006 by John W. Huffman and colleagues to examine the nature of ligand binding to the CB1 receptor.{{cite journal | vauthors = Huffman JW, Padgett LW, Isherwood ML, Wiley JL, Martin BR | title = 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors | journal = Bioorganic & Medicinal Chemistry Letters | volume = 16 | issue = 20 | pages = 5432–5 | date = October 2006 | pmid = 16889960 | doi = 10.1016/j.bmcl.2006.07.051 }}
Legality
In the United States JWH-145 is not federally scheduled, although some states have passed legislation banning the sale, possession, and manufacture of JWH-145.{{UnitedStatesCode2|21|812|Schedules of controlled substances}}{{cite web |title=The 2020 Florida Statutes |url=http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/Sections/0893.03.html |website=www.leg.state.fl.us |access-date=20 August 2021}}{{cite web |title=Arizona Revised Statutes Title 13. Criminal Code § 13-3401 |url=https://www.azleg.gov/ars/13/03401.htm |website=www.azleg.gov |access-date=20 August 2021}}{{cite web |title=California Code, Health and Safety Code - HSC § 11357.5 |url=https://codes.findlaw.com/ca/health-and-safety-code/hsc-sect-11357-5.html |website=Findlaw}}
In Canada, JWH-145 and other naphthoylpyrrole-based cannabinoids are Schedule II controlled substances under the Controlled Drugs and Substances Act.{{cn|date=September 2021}}
In the United Kingdom, JWH-145 and other naphthoylpyrrole-based cannabinoids are considered Class B drugs under the Misuse of Drugs Act 1971.{{cn|date=September 2021}}
See also
References
{{reflist}}
{{Cannabinoids}}
Category:CB1 receptor agonists
Category:CB2 receptor agonists
{{Cannabinoid-stub}}